AI in Oncology Market Size & Share 2026-2035

AI in Oncology Market Size

The global AI in oncology market was valued at USD 3.1 billion in 2025. It is projected to increase from USD 3.7 billion in 2026 to USD 32 billion by 2035, representing a 27.2% CAGR. The market includes AI software, enabling hardware, and services used in cancer detection, diagnosis, treatment planning, drug discovery, clinical development, and oncology care delivery.

Cancer volume supplies a durable demand base, but it does not by itself create a deployable AI market. IARC reported 20 million new cancer cases and 9.7 million cancer deaths globally in 2022, and projects more than 35 million new cases in 2050 ^{[1]WHO/IARC, Global cancer burden growing, amidst mounting need for services, February 2024, who.int}. Breast cancer accounted for 2.3 million cases in 2022, while lung cancer caused 1.8 million deaths; both have repeatable imaging, pathology, and molecular-testing workflows that can generate the labelled data needed for commercial algorithms.

The earlier market was concentrated in image interpretation and molecular testing. Its next phase depends on whether vendors can connect imaging, pathology, genomic, and clinical records inside care workflows rather than offer isolated alerts. FDA authorizations demonstrate a growing base of regulated clinical AI: a review identified 71 oncology AI devices authorized through 2021, with radiology and pathology representing the largest shares ^{[2]Tian et al., AI in Oncology: Current Landscape and Future Directions, PMC/NIH, 2024, pmc.ncbi.nlm.nih.gov}. In 2024, radiology accounted for 74.4% of ML-enabled medical-device authorizations across clinical areas.

The market is therefore unlikely to scale evenly across all providers. Vendors that can pair regulated applications with implementation capacity and reusable data assets should capture a disproportionate share of enterprise contracts. Smaller point-solution suppliers can still grow in indications with a clear workflow and reimbursement pathway, but their route to scale is more likely to involve channel partnerships, platform integration, or acquisition.

The market is assessed globally from 2022 through 2035, with 2025 as the base year and 2026–2035 as the forecast period. Global market value was USD 3,064.05 million in 2025 and is projected to reach USD 31,963.2 million by 2035 at a 27.2% CAGR.

Key Drivers

Early cancer detection demand is converting AI from an experimental reading aid into throughput infrastructure.

The MASAI randomized screening study found that AI-supported mammography reduced screen-reading workload by 44% while maintaining cancer-detection performance comparable with standard double reading. That evidence matters commercially because screening programs face a limited supply of specialist readers. Lunit's digital breast tomosynthesis product received FDA 510(k) clearance in November 2023 ^{[3]Lunit, FDA Clearance for Lunit INSIGHT DBT, November 2023, lunit.io}, followed by clearance for version 1.1 in October 2024. In prostate pathology, Ibex received FDA 510(k) clearance for its Prostate Detect product in February 2025. These cases show that adoption is moving where performance can be validated against an established diagnostic workflow.

Cancer prevalence widens the addressable workflow burden.

The United States recorded 1,941,540 invasive cancers diagnosed in 2023, while the EU reported 1.16 million cancer deaths in 2023. High-volume cancers create immediate demand for image review, pathology interpretation, and therapy selection; lower-resource markets create a different need for triage and remote specialist support. Qure.ai reported deployments across more than 3,000 imaging sites in over 90 countries after its September 2024 Series D financing. That operating footprint illustrates the relevance of AI where diagnostic capacity, rather than demand, is the binding constraint.

Precision oncology makes data synthesis a clinical and research necessity.

Molecularly guided treatment requires clinicians and drug developers to interpret variants, treatment histories, and outcomes across data types that are not designed to be read together manually. Guardant Health reported USD 687.9 million in 2024 precision-oncology revenue and approximately 206,700 oncology clinical tests, excluding Shield. Flatiron Health's real-world-data platform contains more than 5 million oncology patient records from approximately 280 cancer clinics. These networks provide the structured evidence layer that enables trial matching, biomarker investigation, and outcome modelling, although use of real-world data still requires fit-for-purpose curation.

Digital infrastructure is changing the feasible scope of deployment.

AI is increasingly procured as an enterprise capability when hospitals can connect PACS, pathology systems, EHRs, and cloud services. Aidoc's platform was deployed across more than 150 U.S. hospitals and health systems, including an enterprise rollout across University Hospitals facilities. GE HealthCare reported 85 AI-enabled FDA authorizations in its FY2024 results, while Siemens Healthineers reported EUR 3.84 billion in FY2024 Varian revenue. Installed imaging and treatment-planning bases give these vendors a distribution advantage because AI can be embedded in a system already supported by the provider.

Key Restraints

Implementation cost remains broader than the software contract.

A clinical AI deployment can require image or slide digitization, interface work with PACS, RIS, EHR, and laboratory systems, cybersecurity review, workforce training, and post-deployment performance monitoring. Digital pathology is particularly capital-intensive because whole-slide scanners and storage capacity must precede algorithm use. The FDA review of 2024 ML-enabled-device authorizations reported a 162-day median 510(k) review time and found predetermined change-control plans in only 16.7% of submissions. The implication is that vendors and providers must budget for maintaining the validated system, not only for its initial installation.

Regulatory fragmentation limits the portability of clinical evidence.

FDA clearance does not remove the need to meet European MDR or IVDR requirements, and high-risk healthcare AI under the EU AI Act faces documentation, monitoring, and human-oversight obligations ^{[4]EMA, 2024 AI Observatory Report, December 2024, ema.europa.eu}. EMA's 2024 reflection paper also calls for a risk-based approach to AI across the medicinal-product lifecycle. Multijurisdictional launches therefore demand separate regulatory strategies and evidence packages, which can delay product rollouts and favor suppliers that can sustain quality-management and clinical-affairs teams.

This concentrates advantage at two ends of the market. Large medtech suppliers can use installed bases to distribute integrated offerings, while data-rich oncology specialists can defend applications where molecular, pathology, or real-world datasets are central to performance. Point products remain viable when they solve a discrete reimbursable problem, but their bargaining power weakens if they cannot demonstrate a route into the customer's broader data environment.

AI in Oncology Market Segment Analysis

By Component

Software Solutions accounted for USD 1,314.78 million, or 42.9%, of 2025 revenue and are projected to grow at 27.5%. Their lead reflects the move from scanner-bound algorithms toward software deployed across existing imaging, pathology, genomic, and clinical-data environments. Hardware contributed USD 983.25 million, or 32.1%, because digital pathology scanners, accelerated computing, and AI-enabled imaging equipment remain necessary for many workflows. Services contributed USD 766.01 million, or 25.0%, and become more important as health systems integrate multiple modalities and require validation, training, and governance.

Medical imaging remains the most mature clinical entry point, but pathology and genomics are expanding the software addressable base. FDA clearance of the cloud-based Olympus/Odin Medical CADDIE colonoscopy system in September 2024 illustrates the move to remotely deployable diagnostic applications ^{[5]Olympus, Cloud-Based AI Endoscopy FDA Clearance, September 2024, olympusamerica.com}. NVIDIA's January 2025 partnerships with Illumina and Mayo Clinic show the other direction of travel: multiomics AI and pathology foundation models require intensive computing and curated datasets, preserving a role for enabling infrastructure.

By Cancer Type

Breast cancer led 2025 revenue at USD 820.55 million, or 26.78%, followed by lung cancer at USD 754.37 million, or 24.62%. Their scale is supported by high incidence and standardized screening or imaging pathways. Breast cancer has the fastest projected CAGR at 27.8%, aided by mature mammography and tomosynthesis use cases. Lung cancer tools combine image analysis with molecular profiling, making the segment a practical bridge between diagnostic and precision-oncology AI. Prostate cancer generated USD 460.22 million, colorectal cancer USD 383.01 million, and brain tumor USD 349.30 million in 2025; each relies on a different clinical data architecture, from pathology slides and MRI to endoscopy and radiotherapy planning.

The lower 25.1% CAGR for Other Cancer Types should not be read as limited technical potential. Rather, rarer indications generally have smaller labelled datasets and less standardized workflows. PathAI's January 2024 expansion of PathExplore from eight to 14 oncology indications demonstrates how suppliers are extending tumor-microenvironment analysis beyond the highest-volume cancers.

By Application

Drug Discovery was the largest application in 2025 at USD 1,412.53 million, or 46.1%. Oncology drug pipelines create a strong incentive to use models for target identification, molecular design, and compound prioritization before costly clinical-stage decisions. In August 2024, Absci and Memorial Sloan Kettering announced a collaboration to develop biologics for up to six oncology programs using generative AI ^{[6]Absci, Collaboration with MSK using Generative AI, August 2024, investors.absci.com}. The segment's size reflects research spending and platform collaborations rather than routine patient-care deployment.

Cancer Detection and Diagnosis generated USD 802.78 million, while Treatment Planning and Optimization generated USD 658.77 million and has the fastest application CAGR at 27.8%. Planning tools gain value when they can account for anatomy, imaging, and clinical constraints in a repeated treatment workflow; Siemens' Ethos platform is designed to use AI-supported calculations for adaptive radiotherapy. Drug Development and Clinical Trials, at USD 189.97 million, is smaller because evidence generation, protocol redesign, and patient matching have longer adoption cycles and more heterogeneous data requirements.

By End Use

Hospitals led end-use revenue at USD 1,433.98 million, or 46.8%, because they operate the broadest collection of imaging, pathology, treatment, and research workflows. Their advantage can also become a constraint: large installations require longer integration and governance processes. Diagnostics Centers accounted for USD 805.85 million and have the highest forecast CAGR at 27.8%; networked imaging and pathology providers can deploy repeatable AI services across sites without recreating a complete hospital workflow. Specialty Clinics contributed USD 671.03 million, where genomic testing and focused oncology pathways can make targeted deployments practical. Other End Users, principally pharmaceutical, biotechnology, and contract-research organizations, contributed USD 153.20 million.

Segment growth also shifts the competitive question from "which algorithm performs best?" to "which organization can operationalize a decision across sites and modalities?" Software remains the largest component because it captures the analytical layer, while hardware and services remain economically material because data acquisition, compute, and implementation set the ceiling on actual utilization. That linkage favors partnerships between clinical-platform vendors, data-network owners, and infrastructure providers.

AI in Oncology Market Regional Analysis

North America

North America generated USD 1,236.40 million in 2025, or 40.4% of global value, and is projected to grow at 26.96%. The United States accounted for USD 1,151.67 million, or 93.2% of the regional market, while Canada contributed USD 84.73 million. The U.S. combines a mature FDA device pathway, large oncology-provider systems, and sizeable molecular-testing and real-world-data businesses. Guardant360 reimbursement and the growing number of regulated AI devices support commercial confidence, although reimbursement remains uneven by clinical use case ^{[7]Guardant Health, Q4 and Full Year 2024 Financial Results and 2025 Outlook, investors.guardanthealth.com}. Canada's 27.3% CAGR reflects a smaller base with access to clinical-trial and digital-pathology collaborations.

Europe

Europe represented USD 670.17 million in 2025, or 21.9%, and is projected to grow at 26.73%. Germany, the United Kingdom, France, Spain, Italy, and the Netherlands are the principal markets. The region has a substantial disease burden and strong academic centres, but commercial scaling is shaped by country-level procurement, health-technology assessment, and MDR/IVDR requirements. The UK's AI Diagnostic Fund supported deployment of Qure.ai's chest-CT tool, providing an example of a public route from validation to procurement. The EU AI Act and EMA's risk-based guidance make governance capabilities part of market access rather than a back-office consideration.

Asia Pacific

Asia Pacific was the second-largest region at USD 764.99 million, or 24.6%, and is projected to grow fastest at 27.9%. China, Japan, India, Australia, and South Korea contribute different strengths: China and India carry large cancer caseloads, Japan offers a mature medtech market, and South Korea has produced globally active diagnostic-AI vendors. IARC estimated 4.82 million new cancer cases in China and more than 1.41 million in India in 2022. The region's commercial opportunity is not uniform; it combines large-scale screening needs with national regulations, variable hospital digitization, and locally developed procurement channels. Qure.ai's global expansion and Lunit's U.S. hospital presence show that Asia-based firms can use domestic technical capacity as a base for international commercialization.

Latin America

Latin America accounted for USD 220.26 million in 2025, or 7.12%, and is projected to grow at 27.6%. Brazil, Mexico, and Argentina anchor regional demand. Here, AI's most immediate role is often to extend diagnostic and planning capacity where access to pathology and specialist oncology expertise is uneven. A 2025 review of oncology care in Latin America identifies AI-supported imaging and automated radiotherapy planning as potential tools for resource-constrained settings ^{[8]PMC, Transforming Oncology Care in Latin America: AI-Driven Solutions, 2025, pmc.ncbi.nlm.nih.gov}. Adoption will depend on locally workable financing, connectivity, validation in regional populations, and integration with public health systems rather than on the availability of an algorithm alone.

Middle East and Africa

Middle East and Africa generated USD 172.23 million in 2025, or 5.58%, and are projected to grow at 27.3%. South Africa, Saudi Arabia, and the UAE are the principal markets. Gulf investment in digital hospitals can support enterprise deployments, while South African and other resource-constrained settings have a clearer need for AI that augments limited diagnostic and treatment-planning capacity. The opportunity is consequently bifurcated: high-capital hospital modernization in selected Gulf systems and access-oriented triage or planning tools elsewhere. Vendors need different implementation and pricing approaches for those two settings.

Latin America and Middle East & Africa will not follow a simple delayed version of the North American model. Their most valuable deployments may be those that increase screening or treatment-planning reach with fewer specialists and less infrastructure. That places a premium on cloud delivery, implementation support, and evidence generated in local practice. Investors and suppliers should therefore treat regional expansion as a portfolio of distinct commercialization models rather than a sequence of geographic launches.

AI in Oncology Market Share & Competitive Landscape

Market share is shaped by a combination of installed clinical systems, proprietary data, regulatory clearances, and the ability to integrate multiple oncology modalities. GE HealthCare and Siemens Healthineers compete from broad imaging and treatment-platform bases; GE reported 85 AI-enabled FDA authorizations in FY2024 ^{[9]GE HealthCare, Q4 and Full Year 2024 Financial Results, investor.gehealthcare.com}, while Siemens' Varian business anchors its radiotherapy presence. NVIDIA supplies compute and developer infrastructure across imaging, pathology, genomics, and drug discovery rather than competing as a direct clinical provider. Merative contributes clinical-data and imaging-management infrastructure following its separation from IBM Watson Health.

AI-native suppliers are differentiated by the data and workflow they control. Tempus combines genomics, clinical data, and diagnostic operations; in August 2025 it acquired Paige for USD 81.25 million, adding approximately 7 million digitized pathology slides from 45 countries. Paige's pathology assets now strengthen Tempus's multimodal model strategy. Flatiron Health's real-world oncology data platform serves research, regulatory, and biopharmaceutical use cases, while Guardant Health's liquid-biopsy testing business links molecular results to oncology decision support.

Aidoc, Lunit, Ibex Medical Analytics, PathAI, Qure.ai, and SOPHiA GENETICS occupy more focused positions across radiology, pathology, and precision-oncology analytics. Aidoc is extending an enterprise clinical-AI model, Lunit and Qure.ai have built imaging deployments, Ibex and PathAI concentrate on pathology, and SOPHiA GENETICS focuses on distributed genomic analysis. Freenome develops multiomics blood tests for early detection, including its PREEMPT CRC study, and its February 2024 financing supported continued clinical development. The common strategic challenge is converting an indication-specific product into a durable data and workflow position without diluting clinical evidence quality.

Recent Industry Developments

August 2025 - Tempus acquired Paige for USD 81.25 million, primarily in Tempus stock. The transaction added Paige's digital-pathology dataset and foundation-model capabilities to Tempus's oncology data platform.

November 2025 - PathAI announced self-service access to PathExplore through its AISight image-management system, enabling academic medical centres to use tumor-microenvironment analysis for immuno-oncology research.

September 2025 - SOPHiA GENETICS announced an expansion of its collaboration with AstraZeneca to support AI-powered NGS detection of PIK3CA/AKT1/PTEN pathway alterations in breast and prostate cancer.

February 2025 - Ibex Medical Analytics announced FDA 510(k) clearance for Ibex Prostate Detect, its first U.S. clearance for AI-assisted identification of small and rare prostate cancers in tissue biopsies.

January 2025 - NVIDIA announced healthcare partnerships with Illumina, Mayo Clinic, and IQVIA covering multiomics, pathology foundation models, and life-sciences AI.